ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC-Reference-Cited by-同舟云学术

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Published:2020-06-17 Issue:548 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Goswami Sangeeta¹^ORCID,Chen Yulong¹,Anandhan Swetha¹^ORCID,Szabo Peter M.²,Basu Sreyashi³^ORCID,Blando Jorge M.³^ORCID,Liu Wenbin³,Zhang Jan¹,Natarajan Seanu Meena¹,Xiong Liangwen¹,Guan Baoxiang¹,Yadav Shalini Singh³^ORCID,Saci Abdel²^ORCID,Allison James P.³⁴^ORCID,Galsky Matthew D.⁵,Sharma Padmanee¹³⁴^ORCID

Affiliation:

1. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

2. Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ 08540, USA.

3. Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

4. Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

5. Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY 10029, USA.

Abstract

A combination of ARID1A mutation and CXCL13 expression in baseline tumor tissues improves predictive capability for patients with mUCC receiving ICT.

Funder

Parker Institute for Cancer Immunotherapy

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference35 articles.

1. Cancer statistics, 2020

2. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial